Abstract
The Lipoprotein-apheresis (LA) devices used in North America for Familial Hypercholesterolemia (FH) reduce LDL-C (− 80%) by binding positive charged apolipoprotein B (apoB) to a negative charged environment. FH patients also have low HDL-C levels, and despite their negative charge, HDL-C is
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
